期刊文献+

D-氨基葡萄糖抗肿瘤作用机制的研究进展 被引量:2

Research progress on antitumor mechanisms of D-glucosamine
原文传递
导出
摘要 D-氨基葡萄糖是人体内天然存在的氨基己糖,也存在于甲壳类动物的外骨骼中。D-氨基葡萄糖是糖蛋白和蛋白聚糖的重要组成部分,具有抗炎、抗肿瘤、抗氧化、抗纤维化和免疫调节等药理作用,临床上常用于缓解骨关节炎症状。目前已有大量文献报道有关D-氨基葡萄糖抗肿瘤作用的研究成果,其抗肿瘤的作用机制主要包括抑制癌细胞增殖、诱导癌细胞凋亡和细胞周期阻滞、缓解炎症反应、诱导癌细胞自噬死亡、逆转肿瘤耐药性、抑制肿瘤血管生成、抑制基质金属蛋白酶的表达、调控转录因子以及免疫调节作用等。通过查阅国内外相关文献报道,综述了D-氨基葡萄糖抗肿瘤作用机制的研究进展,以期为D-氨基葡萄糖的深入研究提供参考。 D-glucosamine is a hexosamine that is produced naturally in human body, which is also found in the exoskeleton of crustaceans. It is an important component of glycoproteins and proteoglycans. D-glucosamine has many pharmacological properties, including anti-inflammatory, antitumor, antioxidant, anti-fibrosis and immune regulation. It is often used to relieve osteoarthritis in clinical. At present, numerous literatures have reported the research results of the antitumor activity of D-glucosamine, and the molecular mechanisms of which mainly include the suppression of tumor cell proliferation, promotion of apoptosis and arrest of the cell cycle, the suppression of inflammation, induction of autophagic cell death, reversal of drug-resistance, anti-angiogenic activity, inhibitory effect on matrix metalloproteinases expression, regulation of transcription factors, and immunomodulatory effects. This review summarizes antitumor molecular mechanisms of D-glucosamine in details, in order to provide the scientific basis for the further studies of D-glucosamine.
作者 苏喆 黄哲甦 SU Zhe;HUANG Zhe-su(Tianjin Institute for Drug Control,Tianjin 300070,China)
出处 《现代药物与临床》 CAS 2020年第6期1268-1274,共7页 Drugs & Clinic
基金 重大新药创制国家科技重大专项(2019ZX09721001-006-001) 国家自然科学基金面上项目(31970667) 国家药典委员会药品标准制修订研究课题(2019H03) 天津市“131”创新型人才培养工程项目。
关键词 D-氨基葡萄糖 抗肿瘤 作用机制 D-glucosamine antitumor mechanism of action
  • 相关文献

参考文献8

二级参考文献64

  • 1潘奇,王鲁,孙惠川,刘银坤,叶胜龙,汤钊猷.不同转移潜能人肝癌细胞系转录因子活性差异分析[J].中华肝脏病杂志,2006,14(1):37-40. 被引量:21
  • 2郭晓强.肝杀菌肽与酒精性肝病相关的铁过剩[J].生命的化学,2007,27(3):239-240. 被引量:3
  • 3Artavanis-Tsakona S, Matsuno K, Fortini ME. Notch signaling[J].Seience,1995,268 (5208) : 225 -232.
  • 4Li JL, Sainson RC, Shi W, et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. [ J ]. Cancer Res, 2007,67(23) :11244 - 11253.
  • 5Hellstrrm M, Phng LK, Hofmann JJ, et al. DLL4 signaling through Notch I regulates formation of tip cells during angiogenesis[J]. Nature,2007,445(7129) :776-780.
  • 6Williams CK, Li JL, Murga M, et al. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function[J]. Blood,2006,107(3) : 931 -939.
  • 7Siekmann AF, Covassin L, Lawson ND. Modulation of VEGF signaling output by the Notch pathway [J].Bio Essays,2008,30(4) :303 -313.
  • 8Folkman J. Tumor angiogenesis therapeutic implication [ J ]. J Invest Dermstol,1972,59 (1) : 40-43.
  • 9Jain RK, Duda DG, Clark JW, et al. Lessons from phase III clinical trials on anti- VEGF therapy for cancer [ J ]. Nat Clin Pract Oncol,2006,3 ( 1 ) :24 - 40.
  • 10Ridgway J, Zhang G, Wu T, et al. Inhibition of DLL4 signaling inhibits tumor growth by deregulating angiogenesis [ J ] . Nature,2006,444(7122) :1083 -1087.

共引文献66

同被引文献20

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部